Products Mirabegron + Placebo
Mirabegron + Placebo Approved Completed ⚡ Active Interest: 43/100
May 1, 2014 → Jun 1, 2019
About Mirabegron + Placebo Mirabegron + Placebo is a approved stage product being developed by Astellas Pharma for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02086188. Target conditions include Multiple Sclerosis.
What happened to similar drugs? 20 of 20 similar drugs in Multiple Sclerosis were approved
Clinical Trials (9) NCT ID Phase Status Start Completion Indication NCT04641975 Phase 3 Terminated Mar 15, 2021 Jul 24, 2023 Overactive Bladder (OAB) NCT02787083 Phase 3 Terminated Aug 1, 2016 Jul 5, 2019 Cystitis, Interstitial NCT02216214 Approved Completed Oct 7, 2014 Jan 2, 2018 Overactive Bladder (OAB) NCT02086188 Approved Completed May 1, 2014 Jun 1, 2019 Multiple Sclerosis NCT02092181 Approved Completed Mar 1, 2014 Jul 1, 2018 Parkinsons Disease NCT01284309 Phase 1 Completed Nov 1, 2010 Feb 1, 2011 Intraocular Pressure NCT00912964 Phase 3 Completed Apr 28, 2009 Apr 27, 2010 Urinary Bladder, Overactive NCT00662909 Phase 3 Completed Mar 28, 2008 Apr 22, 2009 Urinary Bladder, Overactive NCT00410514 Phase 2 Completed Dec 1, 2006 Aug 1, 2008 Lower Urinary Tract Symptoms
Product Company Stage Hype Score mRNA-1195 Moderna Phase 2 NEX-20A Nanexa AB Phase 1 mRNA-2736 Moderna Phase 1 mRNA-2808 Moderna Phase 2 Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2